Sunshine Biopharma Inc. (NASDAQ: SBFM) has advanced its lead coronavirus drug candidate into IND-enabling studies. The small-molecule PLpro protease inhibitor demonstrates nanomolar potency and broad-spectrum activity against SARS-CoV-2 variants of concern.

The company previously published laboratory results on its library of anti-coronavirus compounds in August 2024 and March 2026. These publications are available on the company website.

Preclinical Profile and Efficacy

The nominated drug candidate displayed desirable ADME profiles and was assessed in a general mammalian toxicology study in rats. Key preclinical findings include:

• Nanomolar potency against the viral protease
• Broad-spectrum activity against SARS-CoV-2 variants in vitro
• High oral bioavailability in mice, rats, and dogs
• Preferential lung enrichment in mice and rats
• Significant dose-dependent suppression of pulmonary viral replication in K18-hACE2 mice infected with human SARS-CoV-2

Strategic Outlook

Dr. Steve Slilaty, CEO of Sunshine Biopharma, described the advancement as a strategically significant development that validates the company's discovery infrastructure. He noted the compound's profile places the company in a highly competitive position for next-generation coronavirus therapeutics.

Sunshine Biopharma currently markets 60 generic prescription drugs in Canada, with approximately 12 additional drugs scheduled for launch in the remainder of 2026. Its proprietary development program also includes K1.1 mRNA, an mRNA-lipid nanoparticle targeted for liver cancer.

Sunshine Biopharma Inc. (NASDAQ: SBFM) has obtained regulatory approval from Health Canada for its generic Atenolol tablets, available in 25mg, 50mg, and 100mg strengths. The approval marks a strategic expansion into cardiovascular care for the Fort Lauderdale-based pharmaceutical company.

Atenolol is a beta-blocker that lowers heart rate and blood pressure by blocking natural chemicals such as epinephrine. It serves as a generic equivalent to the brand-name drug Tenormin.

Therapeutic Indications

The approved medication targets three primary cardiovascular conditions:

• Hypertension Management: Lowering high blood pressure to mitigate risks of strokes, heart attacks, and kidney problems.
• Angina Pectoris: Treating chest pain resulting from reduced blood flow to the heart muscle.
• Post-Myocardial Infarction: Improving survival rates when administered clinically after a heart attack.

Market Context and Distribution

The global Atenolol market is projected to grow at a compound annual growth rate (CAGR) of 7.3%, rising from $12.45 billion in 2025 to $17.85 billion in 2030, according to Research and Markets. The Canadian pharmaceutical market represents approximately 2.1% of the global total, ranking sixth worldwide per IQVIA Pharmafocus 2028 data.

Sunshine Biopharma will distribute the drug through Nora Pharma Inc., its wholly owned Canadian subsidiary. The company currently markets 60 generic prescription drugs in Canada and plans to launch approximately 12 additional products in the remainder of 2026. Atenolol shipments are expected to reach pharmacies by the end of 2026.

What the Numbers Show

The addition of Atenolol diversifies Sunshine Biopharma’s existing portfolio, which is heavily weighted toward generics. With 60 approved drugs already on the Canadian market and 12 more slated for late 2026, the company is executing a high-volume launch strategy. This approach leverages its established distribution network to capture share in a growing therapeutic segment, rather than relying solely on proprietary development pipelines like its K1.1 mRNA or PLpro protease inhibitor programs.